Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.
Sera of patients with cancer contain membraneous microvesicles (MV) able to induce apoptosis of activated T cells by activating the Fas/Fas ligand pathway. However, the cellular origin of MV found in cancer patients' sera varies as do their molecular and cellular profiles. To distinguish tumor-derived MV in cancer patients' sera, we used MAGE 3/6(+) present in tumors and MV. Molecular profiles of MAGE 3/6(+) MV were compared in Western blots or by flow cytometry with those of MV secreted by dendritic cells or activated T cells. These profiles were found to be distinct for each cell type. Only tumor-derived MV were MAGE 3/6(+) and were variably enriched in 42-kDa Fas ligand and MHC class I but not class II molecules. Effects of MV on signaling via the TCR and IL-2R and proliferation or apoptosis of activated primary T cells and T cell subsets were also assessed. Functions of activated CD8(+) and CD4(+) T lymphocytes were differentially modulated by tumor-derived MV. These MV inhibited signaling and proliferation of activated CD8(+) but not CD4(+) T cells and induced apoptosis of CD8(+) T cells, including tumor-reactive, tetramer(+)CD8(+) T cells as detected by flow cytometry for caspase activation and annexin V binding or by DNA fragmentation. Tumor-derived but not dendritic cell-derived MV induced the in vitro expansion of CD4(+)CD25(+)FOXP3(+) T regulatory cells and enhanced their suppressor activity. The data suggest that tumor-derived MV induce immune suppression by promoting T regulatory cell expansion and the demise of antitumor CD8(+) effector T cells, thus contributing to tumor escape.
Wieckowski
Eva U
EU
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Visus
Carmen
C
Szajnik
Marta
M
Szczepanski
Miroslaw J
MJ
Storkus
Walter J
WJ
Whiteside
Theresa L
TL
D000951:Antigens, Neoplasm / Q000032:analysis; D017209:Apoptosis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D055252:Cell-Derived Microparticles / Q000276:immunology* / Q000473:pathology; D002478:Cells, Cultured; D053222:Fas Ligand Protein / Q000032:analysis; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006801:Humans; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis; D050378:T-Lymphocytes, Regulatory / Q000502:physiology*; D019139:Tumor Escape / Q000276:immunology*
D000951:Antigens, Neoplasm; D053222:Fas Ligand Protein; D015395:Histocompatibility Antigens Class I; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins
J Immunol Methods. 1991 Dec 15;145(1-2):185-92
1765650
Proteomics. 2004 Dec;4(12):4019-31
15478216
Clin Cancer Res. 2007 Nov 1;13(21):6301-11
17975141
Cancer Res. 1999 Apr 1;59(7):1422-7
10197606
J Immunol. 2008 Jun 1;180(11):7249-58
18490724
Adv Immunol. 2006;92:187-224
17145305
Cancer Res. 2006 Sep 15;66(18):9290-8
16982774
Hum Gene Ther. 1996 Mar 1;7(4):479-87
8800742
Cancer Res. 2007 Apr 1;67(7):2912-5
17409393
Immunol Lett. 2006 Nov 15;107(2):102-8
17067686
Am J Pathol. 2004 May;164(5):1807-15
15111327
Trends Cell Biol. 2009 Feb;19(2):43-51
19144520
J Biochem. 2006 Jul;140(1):13-21
16877764
Cancer Res. 2003 Sep 1;63(17):5573-81
14500397
Clin Cancer Res. 2005 Feb 1;11(3):1010-20
15709166
J Immunol. 1999 Aug 1;163(3):1274-81
10415024
Blood Cells Mol Dis. 2006 Mar-Apr;36(2):315-21
16487731
Transplantation. 2006 Aug 15;82(3):295-303
16906023
J Exp Med. 2002 May 20;195(10):1303-16
12021310
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11671-6
16855047
Cancer Res. 2007 Aug 1;67(15):7458-66
17671216
J Immunol. 2007 Jan 1;178(1):320-9
17182569
J Immunol Methods. 2003 Aug;279(1-2):1-15
12969543
Clin Cancer Res. 2006 Jul 1;12(13):3890-5
16818683
Head Neck. 2009 Mar;31(3):371-80
19073006
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):122-8
16027013
Clin Cancer Res. 2003 Feb;9(2):606-12
12576425
J Immunol. 2006 Feb 1;176(3):1534-42
16424182
J Biol Chem. 2007 Jun 1;282(22):15954-64
17392282
Nat Med. 2004 Sep;10(9):942-9
15322536
Br J Cancer. 2005 Jan 31;92(2):305-11
15655551
J Immunol. 2007 Aug 1;179(3):1969-78
17641064
J Cancer Res Clin Oncol. 2007 Jun;133(6):389-99
17219198
Exp Cell Res. 2004 May 1;295(2):315-29
15093732
J Immunol. 2008 Mar 1;180(5):2967-80
18292519
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):89-93
15990342
Nat Cell Biol. 2008 May;10(5):619-24
18425114
Nat Rev Immunol. 2007 Jul;7(7):532-42
17589543
Br J Cancer. 2005 Jan 31;92(2):209-11
15702078
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):153-7
16099697
Am J Respir Cell Mol Biol. 2004 Jul;31(1):114-21
14975938
Mol Immunol. 2006 Apr;43(11):1872-80
16368145
Cancer Res. 1999 Oct 15;59(20):5356-64
10537320
Semin Cancer Biol. 2006 Feb;16(1):3-15
16153857
Clin Cancer Res. 2008 Jun 15;14(12):3706-15
18559587
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6910-5
9192665
Cell Death Differ. 2009 May;16(5):708-18
19180118
Cancer Res. 1989 Sep 15;49(18):5167-75
2766286
Leukemia. 2006 Sep;20(9):1487-95
16791265
J Cell Sci. 2000 Oct;113 Pt 19:3365-74
10984428
Clin Cancer Res. 2003 Nov 1;9(14):5113-9
14613988